gonadotropins plus GnRH antagonists + ganirelix
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
INFERTILITY
Conditions
INFERTILITY, Fertility Preservation, Ovulation Induction, Vitrification, Oocyte Donation
Trial Timeline
Jul 1, 2012 → Dec 1, 2013
NCT ID
NCT01645241About gonadotropins plus GnRH antagonists + ganirelix
gonadotropins plus GnRH antagonists + ganirelix is a pre-clinical stage product being developed by Merck for INFERTILITY. The current trial status is completed. This product is registered under clinical trial identifier NCT01645241. Target conditions include INFERTILITY, Fertility Preservation, Ovulation Induction.
What happened to similar drugs?
16 of 20 similar drugs in INFERTILITY were approved
Approved (16) Terminated (4) Active (4)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01645241 | Pre-clinical | Completed |
Competing Products
20 competing products in INFERTILITY